8-K: InspireMD Announces Positive Clinical Trial Results and Second Quarter 2024 Financials

InspireMD reported positive one-year outcomes from its C-GUARDIANS clinical trial and a 5.4% increase in second-quarter revenue, while also detailing increased operating expenses.

Summary

• InspireMD announced positive one-year results from the C-GUARDIANS IDE clinical trial for its CGuard Prime carotid stent system, showing a 1.95% primary endpoint event rate, the lowest for any carotid stent or embolic protection device pivotal trial.
• The company is on track to submit a Premarket Approval (PMA) application to the FDA this quarter.
• InspireMD raised $17.9 million in gross proceeds from the full exercise of Series H warrants.
• Second quarter 2024 revenue was $1.74 million, a 5.4% increase compared to the same period in 2023, driven by growth in existing and new markets.
• Gross profit for the second quarter decreased by 32.6% to $331,000 due to increased material and labor costs.
• Total operating expenses for the second quarter increased by 48.0% to $8.591 million, primarily due to increased compensation and development expenses.
• The net loss for the second quarter of 2024 was $7.909 million, or $0.22 per share, compared to a net loss of $5.077 million, or $0.24 per share, for the same period in 2023.
• Cash, cash equivalents, and marketable securities totaled $47.2 million as of June 30, 2024, compared to $39.0 million as of December 31, 2023.
• For the six months ended June 30, 2024, revenue increased by 12.5% to $3.25 million, while gross profit decreased by 27.9% to $623,000.
• The net loss for the six months ended June 30, 2024, was $14.941 million, or $0.43 per share, compared to a net loss of $9.333 million, or $0.64 per share, for the same period in 2023.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While the clinical trial results are very positive and the company is progressing with regulatory submissions, the financial results show increased losses and decreased gross profit. The sentiment is cautiously optimistic due to the clinical success but tempered by the financial challenges.

Positives

• The C-GUARDIANS trial showed a best-in-class one-year primary endpoint event rate of 1.95%.
• The company is on track to submit a PMA application to the FDA this quarter.
• The full exercise of Series H warrants resulted in $17.9 million in gross proceeds.
• Second quarter revenue increased by 5.4% year-over-year.
• The number of CGuard stents sold increased by nearly 6% compared to the second quarter of 2023.
• InspireMD completed enrollment in the CREST-2 clinical trial.
• The company is progressing with the CGUARDIANS II TCAR clinical trial.

Negatives

• Gross profit for the second quarter decreased by 32.6% due to increased material and labor costs.
• Total operating expenses for the second quarter increased by 48.0%, primarily due to increased compensation and development expenses.
• The net loss for the second quarter of 2024 was $7.909 million, compared to a net loss of $5.077 million for the same period in 2023.
• Gross margin decreased to 19.0% during the three months ended June 30, 2024, from 29.8% during the three months ended June 30, 2023.

Risks

• The company has a history of recurring losses and negative cash flows from operating activities.
• There is uncertainty regarding the adequacy of the company's liquidity to pursue its business objectives.
• The company may need to raise additional capital, which could be costly or difficult to obtain and could dilute stockholders' ownership interests.
• There are risks associated with market acceptance of the company's products and the ability to secure and maintain regulatory approvals.
• Negative clinical trial results or lengthy product delays in key markets could impact the company.
• The company faces intense competition in its industry.
• There are risks associated with conducting business in multiple foreign jurisdictions, including currency exchange rate fluctuations and political instability.
• The escalation of hostilities in Israel could impair the company's ability to manufacture its products.

Future Outlook

InspireMD intends to proceed with a PMA application in the back half of this year and anticipates FDA approval in the first half of 2025. The company also plans to initiate the CGUARDIANS II clinical trial in the back half of this year.

Management Comments

• Marvin Slosman, CEO of InspireMD, stated that the announcement of best-in-class one-year outcomes data from the C-GUARDIANS clinical trial was a clear highlight.
• Mr. Slosman also mentioned that the company intends to proceed with a PMA application in the back half of this year while continuing to build out a world-class US commercial infrastructure.
• Mr. Slosman noted that the company is on track to initiate the CGUARDIANS II clinical trial in the back half of this year.
• Mr. Slosman believes the company is well positioned for the ongoing paradigm shift toward an endovascular stent first approach.

Industry Context

This announcement is significant for the medical device industry, particularly in the carotid artery disease treatment space. The positive clinical trial results for the CGuard Prime stent system could position InspireMD as a leader in this market. The company's focus on both Carotid Artery Stenting (CAS) and Transcarotid Arterial Revascularization (TCAR) aligns with the industry's move towards endovascular solutions.

Comparison to Industry Standards

• The 1.95% primary endpoint event rate in the C-GUARDIANS trial is notably lower than rates reported in other pivotal trials for carotid stents and embolic protection devices, such as the SAPPHIRE trial which reported a 6.7% rate at 30 days and the CREST trial which reported a 7.2% rate at 4 years.
• Companies like Abbott and Medtronic, which also have carotid stent products, have reported varying results in their clinical trials, but InspireMD's 1.95% rate is a standout figure.
• The company's focus on both CAS and TCAR positions them well against competitors who may only focus on one approach, such as Silk Road Medical which focuses on TCAR.
• The revenue growth of 5.4% in Q2 2024 is modest compared to some larger medical device companies, but the focus on clinical trial success and regulatory approval is a key differentiator for InspireMD at this stage.

Stakeholder Impact

• Shareholders may be encouraged by the positive clinical trial results and the potential for FDA approval, but concerned about the increased losses and decreased gross profit.
• Employees may benefit from the company's growth and expansion, but may also be impacted by the increased operating expenses.
• Customers may benefit from the company's innovative products and solutions.
• Suppliers may see increased demand for their products and services.
• Creditors may be concerned about the company's increased losses and negative cash flows.

Next Steps

• Submit a Premarket Approval (PMA) application to the FDA this quarter.
• Continue building out a world-class US commercial infrastructure.
• Initiate the CGUARDIANS II clinical trial in the back half of 2024.

Key Dates

Keywords

carotid stent, CGuard Prime, clinical trial, PMA application, FDA, revenue, gross profit, operating expenses, net loss, warrants, stroke prevention, medical device